Proxima MammoSite RTS For Early-Stage Breast Cancer To Launch By May 17
This article was originally published in The Gray Sheet
Executive Summary
Proxima Therapeutics will emphasize its single-catheter MammoSite radiation therapy system's ease of use over multi-catheter competitor devices in treating early-stage breast cancer
You may also be interested in...
Cautious Report Unlikely To Slow Partial-Breast Irradiation Market, Firms Say
In its most recent assessment of accelerated partial-breast irradiation (APBI), the BlueCross BlueShield Association Technology Evaluation Center reiterated that APBI as the sole radiation treatment following breast-conserving surgery for early stage cancer has not been proven beneficial. But companies in the budding APBI market say the report does not deter them from marketing or developing their treatments (see chart: "1FDA-Cleared APBI Devices ")
Cautious Report Unlikely To Slow Partial-Breast Irradiation Market, Firms Say
In its most recent assessment of accelerated partial-breast irradiation (APBI), the BlueCross BlueShield Association Technology Evaluation Center reiterated that APBI as the sole radiation treatment following breast-conserving surgery for early stage cancer has not been proven beneficial. But companies in the budding APBI market say the report does not deter them from marketing or developing their treatments (see chart: "1FDA-Cleared APBI Devices ")
Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
Cytyc likely will divest Proxima Therapeutics' GliaSite brain tumor radiation therapy system after acquiring the company for its MammoSite breast cancer system under a $160 mil. deal Feb. 9